Using PubGrade’s Research Analytics platform, we analysed NIH grants awarded for genomics, transcriptomics, proteomics, metabolomics, and broader multiomics applications in hematology, the molecular backbone of research in leukemias, lymphomas, anemias, and coagulation disorders. The headline: 2025 started slowly, but a powerful Q3 rebound has pushed hematology funding ahead of 2024 levels as of September.

Early 2025 looks muted, with January, February, May, and June all falling behind their 2024 equivalents. This softness mirrors what we’ve seen in other NIH segments, delayed review cycles, shifting timelines, and slower early-year commitments. For teams relying on NIH-funded labs as prospects, this kind of dip can often feel like cooling demand. But the 2025 pattern is more timing-related than structural. Because then everything changes in Q3.
 

Q3 Delivers a Sharp Rally

The data show a clear inflection point:

- Total hematology OMICs funding in Q3 2025 exceeds Q3 2024

- The Q3 jump is large enough to fully erase the early-year lag

- By September, 2025 is marginally ahead of 2024 in total NIH OMICs dollars awarded

This isn’t just a rebound, it’s a signal that funding momentum remains healthy and that OMICs-heavy hematology programs continue to remain a meaningful priority.
 

More Grants, More Money, Higher Average Award Size

July–August tell an even clearer story:

That means:

> More grants awarded
> More total dollars awarded
> Higher average award size

This suggests not just pent-up activity, but renewed strength in hematology OMICs investment heading into late Q4 and early 2026.
 

Why This Matters for Scientific Marketers and Sales Teams

If you are selling into sequencing, single-cell, proteomics, multiomics, hematology workflows, or data-analysis infrastructure, the shift in funding dynamics matters:

- You may see new opportunities surface later in the year, rather than the traditional early-spring peak
- Labs that appeared quiet in early 2025 may now be ramping up hiring, procurement, or technology evaluation
- Higher award sizes and more grants mean more labs moving into active purchasing cycles
- Knowing which labs have received funding, and when, is crucial for timing outreach, planning campaigns, and prioritising accounts.
 

Want deeper insights into your market?

If you’d like to understand:

- How much NIH funding has been issued in your field
- Which labs have received the latest awards
- Which technologies they’re investing in
- Or how these trends impact your sales cycle

Get in touch and tell us what you want to explore. Contact us, we’ll pull the data you need.